Komboglyze: new hypoglycaemic combination

Bristol-Myers Squibb and AstraZeneca have launched Komboglyze, a fixed-dose combination of saxagliptin and metformin.

The combination tablet is taken twice daily at mealtimes.
The combination tablet is taken twice daily at mealtimes.

The tablets are licensed for use in patients with type II diabetes inadequately controlled by metformin alone and in those currently receiving the combination as separate tablets, or with insulin when insulin plus metformin is inadequate.

Komboglyze provides fixed doses of two hypoglycaemic agents with complementary mechanisms of action: saxagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.

Greater HBA1c reduction than placebo

In a 12-week study, 160 patients whose blood glucose levels were not adequately controlled by metformin alone were randomised to receive placebo or saxagliptin 2.5mg twice daily in addition to metformin.

After 12 weeks, patients in the saxagliptin plus metformin group had a greater reduction in HbA1c than those in the placebo plus metformin group (0.6% vs 0.2%, p=NS).

Efficacious in combination with insulin

In another study, 455 patients with diabetes inadequately controlled by insulin or insulin plus metformin were randomised to receive saxagliptin 5mg or placebo as add-on therapy. After 24 weeks, significant improvements in HbA1c and postprandial glucose were observed in the saxagliptin add-on group compared with the placebo group.

View Komboglyze drug record

Further information: BMS/AstraZeneca

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...